RxDoctor Payments Data

Joshua Smith, PA

Physician Assistant · Henderson, NVNPI 1104122746

Payments from drug & device makers

$2,151in general payments, 2019–2025

Across 127 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$656
  • Novo Nordisk$499
  • Lilly USA, LLC$118
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$81
  • Exact Sciences$70
  • Pfizer$69
  • plus $658 from 21 others

What the payments were for

  • Food & beverage$2,151100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,151 in reported general payments places this provider in the 75th percentile of 881 physician assistant providers in Nevada.

See all physician assistant providers in Nevada

Medicare billing

Part B allowed, 2024
$175,759
Medicare patients
261
Services billed
3,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide132$211,173
JardianceEmpagliflozin53$66,974
RybelsusSemaglutide22$57,081
EliquisApixaban40$44,219
TrulicityDulaglutide19$31,622
Tresiba Flextouch U-100Insulin Degludec41$30,699
LinzessLinaclotide31$28,968
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$26,737
WegovySemaglutide18$22,765
VascepaIcosapent Ethyl14$8,312
Breo ElliptaFluticasone/Vilanterol14$5,175
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,855
Albuterol Sulfate HfaAlbuterol Sulfate100$3,717
Diltiazem 12hr ErDiltiazem Hcl11$3,502
Atorvastatin Calcium405$3,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$499$291,018172 claims
Boehringer IngelheimJardiance$31$66,97453 claims
PfizerEliquis$69$44,21940 claims
GSKTrelegy Ellipta, Breo Ellipta$60$31,91248 claims
Lilly USA, LLCTrulicity$118$31,62219 claims
AbbVieLinzess, Synthroid$656$29,52543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 881 physician assistant providers in Nevada.

Other physician assistant in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →